ASIX AdvanSix Inc.
AdvanSix Inc., integrated chemistry company, engages in the manufacture and sale of polymer resins in the United States and internationally. The company offers Nylon 6, a polymer resin, which is a synthetic material used to produce fibers, filaments, engineered plastics, and films. It also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone that are used in the production of adhesives, paints, coatings, solvents, herbicides, and resins. In addition, the company offers intermediate chemicals, including phenol, alpha-methylstyrene, cyclohexanone, oximes, cyclohexanol, and alkyl and specialty amines; and cyclohexanol, sulfuric acid, ammonia, and carbon dioxide, as well as automotive components, water treatment, and pharmaceutical intermediates. It offers its products under the Aegis, Sulf-N, Nadone, Naxol, and EZ-Blox under brand names. The company sells its products directly and through distributors. AdvanSix Inc. was incorporated in 2016 and is headquartered in Parsippany, New Jersey.…
Industry Peers
ChemicalsKey Statistics
About AdvanSix (NYSE: ASIX)
›
AdvanSix (NYSE: ASIX) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Chemicals industry, part of the Basic Materials sector, and reports about 1,410 employees.
The shares were at 13.49 USD on 19 November 2026, down 11.8% over 52 weeks. Its 52-week range is 13.40 USD to 26.73 USD, and it trades at the bottom of that range.
Its market capitalisation is 364.35M USD. It pays a dividend yielding 4.55% (it pays out 178% of its earnings), against a median of 4.10% among the dividend payers in that peer group.
AdvanSix reports return on equity of 6.0%, an operating margin of 0.4% and revenue up 15.0% year over year.
Its debt exceeds its cash by 388.03M USD, a debt-to-equity ratio of 0.47. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 18.00 USD is 33.4% above the current price. The next earnings report is expected on 19 February 2027.